Take the next step with Foresight® Carrier Screen
Request more information or explore ordering options to bring Foresight to your practice.
Guide family planning decisions for parents of every ancestry
Through proven, superior technology, Foresight is designed to maximize the detection of couples at risk of passing down a serious, inheritable condition to their baby.
Why screen with Foresight?
Screen for diseases that matter most
Bigger is not always better. Foresight’s carefully selected panel of 267 genes prioritizes clinical significance. These genes were selected based on associated condition severity, condition prevalence, clinical actionability of results, and detection sensitivity.
Detect at-risk couples with unmatched technology
Foresight offers the highest published at-risk couple detection rate for serious inherited conditions (1 in 22 couples)1 in our Universal panel. You can trust both positive and negative screening results – the detection rate for the vast majority of genes on our panel is over 99% across ethnicities.2
Test with a proven, trusted partner
Foresight’s Universal panel is the only expanded carrier screening test with published analytical validation in a peer-reviewed journal in the US, backed by 20+ peer-reviewed publications and >2M patients screened.
Flexible panel choices for personalized care
Foresight offers four panel choices that allow you to test for up to 267 genes associated with serious and prevalent inherited conditions.
Fundamental
Cystic fibrosis, spinal muscular atrophy, and fragile X
Fundamental Plus
Focused set of 14 conditions, including ACOG-recommended conditions associated with ethnicity
Universal
176 conditions associated with serious and prevalent inherited conditions
Universal Plus
Comprehensive panel of 267 conditions including ACMG Tier 3 category recommended conditions*
Panels may be customized based on clinical needs.
* F8 and FXN genes recommended by ACMG are not included
Guide informed planning and preparation
Foresight’s results help clinicians guide care and empower patients to take action to make the best decision for their families.
Expert patient support at every step
From on-demand patient education to clear results reporting, Myriad offers seamless patient care throughout the entire Foresight screening process.
Foresight patients have unlimited access to one of Myriad’s 50+ board-certified genetic counselors to help understand the steps of carrier and prenatal screenings and their results.
Testing with Foresight is simple
Discuss Foresight screening with your patient and collect a patient sample (blood or saliva)
Submit patient sample and completed Test Request Form to Myriad
Receive results in about two and a half weeks and review with patient
Refer patients to schedule a consultation with Myriad’s board-certified genetic counselors
What to expect with every screen
Actionable
Every Foresight Carrier Screen provides actionable results within two and a half weeks to inform patient care decisions.
Affordable
Myriad is committed to providing patients with access to reliable and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Reliable
Myriad believes in providing the highest quality tests for patients. From prenatal screens to precision medicine, our tests are designed to give healthcare providers and patients the most reliable answer possible.
Related screens and tests
MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
- All-in-one personalized cancer risk assessment
- Evaluates 48 genes associated with 11 different hereditary cancers
- RiskScore® predicts a patient’s 5-year and lifetime risk of developing breast cancer
Designed for everyone regardless of ancestry, BMI, or ability to pay, the Prequel® Prenatal Screen can determine if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as eight weeks.
- The only non-invasive prenatal screening (NIPS) that uses AMPLIFY™ technology
- 99.9% result delivery on the first draw at 10 weeks1
- Accessible and reliable for everybody, regardless of BMI, ancestry, or ability to pay
Foresight resources
References:
- Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018;doi:10.1373/clinchem.2018.286823.
- Foresight® Residual Risk Table. https://myriad-library.s3.amazonaws.com/mwh/disease-detection-fact-sheet.pdf.
- Committee Opinion No. 690 Summary: Carrier Screening in the Age of Genomic Medicine.” 2017. Obstetrics and Gynecology 129 (3): 595–96
- P Gregg, A.R., Aarabi, M., Klugman, S. et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 23, 1793–1806 (2021). https://doi.org/10.1038/s41436-021-01203-z
